The global antacids market size is calculated at USD 7.44 billion in 2024, grew to USD 7.68 billion in 2025, and is predicted to hit around USD 10.29 billion by 2034, poised to grow at a CAGR of 3.3% between 2024 and 2034. The North America antacids market size accounted for USD 3.42 billion in 2024 and is anticipated to grow at the fastest CAGR of 3.35% during the forecast year.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Antacids Market
5.1. COVID-19 Landscape: Antacids Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Antacids Market, By Mechanism of Action
8.1. Antacids Market Revenue and Volume, by Mechanism of Action, 2024-2034
8.1.1 Systemic Antacids
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Non-systemic Antacids
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 9. Global Antacids Market, By Formulation Type
9.1. Antacids Market Revenue and Volume, by Formulation Type, 2024-2034
9.1.1. Tablets
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Liquids
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Others
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 10. Global Antacids Market, By Distribution Channel
10.1. Antacids Market Revenue and Volume, by Distribution Channel, 2024-2034
10.1.1. Hospital pharmacies
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. Drug stores and retail pharmacies
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1.3. Online providers
10.1.3.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 11. Global Antacids Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.1.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.1.4.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.1.5.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.2.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.2.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.2.4.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.2.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.2.5.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.2.6.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.2.7.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.3.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.3.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.3.4.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.3.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.3.5.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.3.6.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.3.7.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.4.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.4.4.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.4.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.4.5.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.4.6.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.4.7.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.5.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.5.4.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.5.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.5.5.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
Chapter 12. Company Profiles
12.1. Infirst Healthcare Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bayer AG
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Pfizer Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Abbott Laboratories
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Cipla Ltd
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Reckitt Benckiser Group PLC
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. WellSpring Pharmaceutical Corporation
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Prestige Consumer Healthcare Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Alkem Laboratories Ltd.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Haleon plc
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample